Literature DB >> 27197152

Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.

Dongjun Peng1, Takashi Tanikawa1, Wei Li1, Lili Zhao2, Linda Vatan1, Wojciech Szeliga1, Shanshan Wan1, Shuang Wei1, Yin Wang1, Yan Liu1, Elzbieta Staroslawska3, Franciszek Szubstarski3, Jacek Rolinski4, Ewelina Grywalska4, Andrzej Stanisławek5, Wojciech Polkowski6, Andrzej Kurylcio6, Celina Kleer7, Alfred E Chang8, Max Wicha9, Michael Sabel8, Weiping Zou10, Ilona Kryczek11.   

Abstract

Myeloid-derived suppressor cells (MDSC) contribute to immune suppression in cancer, but the mechanisms through which they drive metastatic progression are not fully understood. In this study, we show how MDSC convey stem-like qualities to breast cancer cells that coordinately help enable immune suppression and escape. We found that MDSC promoted tumor formation by enhancing breast cancer cell stem-like properties as well as by suppressing T-cell activation. Mechanistic investigations indicated that these effects relied upon cross-talk between the STAT3 and NOTCH pathways in cancer cells, with MDSC inducing IL6-dependent phosphorylation of STAT3 and activating NOTCH through nitric oxide leading to prolonged STAT3 activation. In clinical specimens of breast cancer, the presence of MDSC correlated with the presence of cancer stem-like cells (CSC) and independently predicted poor survival outcomes. Collectively, our work revealed an immune-associated mechanism that extrinsically confers cancer cell stemness properties and affects patient outcome. We suggest that targeting STAT3-NOTCH cross-talk between MDSC and CSC could offer a unique locus to improve cancer treatment, by coordinately targeting a coupled mechanism that enables cancer stemness and immune escape. Cancer Res; 76(11); 3156-65. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197152      PMCID: PMC4891237          DOI: 10.1158/0008-5472.CAN-15-2528

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

Review 2.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors:  Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

5.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

6.  Human TH17 cells are long-lived effector memory cells.

Authors:  Ilona Kryczek; Ende Zhao; Yan Liu; Yin Wang; Linhua Vatan; Wojciech Szeliga; Jeffrey Moyer; Aleksandra Klimczak; Andrzej Lange; Weiping Zou
Journal:  Sci Transl Med       Date:  2011-10-12       Impact factor: 17.956

7.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

9.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

10.  Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion.

Authors:  Jung-Hye Choi; Joon T Park; Ben Davidson; Patrice J Morin; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more
  82 in total

1.  IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.

Authors:  Yinu Wang; Xingyue Zong; Sumegha Mitra; Anirban Kumar Mitra; Daniela Matei; Kenneth P Nephew
Journal:  JCI Insight       Date:  2018-12-06

2.  Biomaterial Scaffolds Recruit an Aggressive Population of Metastatic Tumor Cells In Vivo.

Authors:  Grace G Bushnell; Tejaswini P Hardas; Rachel M Hartfield; Yining Zhang; Robert S Oakes; Scott Ronquist; Haiming Chen; Indika Rajapakse; Max S Wicha; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Cancer Res       Date:  2019-02-26       Impact factor: 12.701

3.  Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling.

Authors:  Si Xiong; Ronghua Wang; Qian Chen; Jing Luo; Jinlin Wang; Zhenxiong Zhao; Yawen Li; Yun Wang; Xiju Wang; Bin Cheng
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 4.  Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance.

Authors:  Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose
Journal:  Oncologist       Date:  2021-01-02

Review 5.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

6.  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.

Authors:  Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Liang Mao; Lei-Lei Yang; Si-Rui Ma; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

7.  The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations.

Authors:  Eriko Yokoi; Seiji Mabuchi; Naoko Komura; Kotaro Shimura; Hiromasa Kuroda; Katsumi Kozasa; Ryoko Takahashi; Tomoyuki Sasano; Mahiru Kawano; Yuri Matsumoto; Michiko Kodama; Kae Hashimoto; Kenjiro Sawada; Tadashi Kimura
Journal:  Oncoimmunology       Date:  2019-09-25       Impact factor: 8.110

Review 8.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 9.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

Review 10.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.